Twenty patients with unresectable non-small cell lung cancer (10 squamous cell carcinoma, 7 adenocarcinoma, 3 large cell carcinoma), previously untreated, received etoposide 300 mg/m2 by oral route days 1-3-5 every three weeks. No complete or partial remissions were observed but only two minor responses. There were 7 stable diseases and 11 progressive diseases. Myelosuppression activity was usually mild and gastro-intestinal side effects were the most prominent. In this trial etoposide by oral route has shown only marginal activity against non-small cell lung cancer.

Etoposide by oral route in the treatment of unresectable non-small cell lung cancer

Scagliotti, G;
1984-01-01

Abstract

Twenty patients with unresectable non-small cell lung cancer (10 squamous cell carcinoma, 7 adenocarcinoma, 3 large cell carcinoma), previously untreated, received etoposide 300 mg/m2 by oral route days 1-3-5 every three weeks. No complete or partial remissions were observed but only two minor responses. There were 7 stable diseases and 11 progressive diseases. Myelosuppression activity was usually mild and gastro-intestinal side effects were the most prominent. In this trial etoposide by oral route has shown only marginal activity against non-small cell lung cancer.
1984
3
5
324
326
Administration, Oral; Aged; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin
Scagliotti, G; Lodico, D; Gozzelino, F; Pescetti, G
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1691683
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact